AstraZeneca Concedes NSCLC Drug Iressa in U.S. Withdrawal
Amid last month's hoopla surrounding AstraZeneca plc's $1.26 billion acquisition of Ardea Biosciences Inc. and CEO David Brennan's decision to step down, the FDA's official withdrawal of lung cancer drug Iressa (gefitinib) was barely a blip on the radar.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST